Toplines: National Survey of Physicians, Findings on Medicare Part D
These toplines provide the results of a 2006 national survey of physicians on their views and experiences related to the new Medicare drug benefit. Topline (.
View the Latest: Prescription Drugs
Filter
-
-
USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies: Summary and Charts
Poll FindingThis document provides key findings from a USA Today/Kaiser/Harvard survey examining Americans’ views on, and experiences with, prescription drugs and the pharmaceutical industry, including drug costs, advertisements, safety issues, government regulation and medical research. Summary and Charts (.
-
Medicare Prescription Drug Coverage: Facts, Options, and Implications
Event Date:EventTestimony by Patricia Neuman, Sc.D.
-
Demand Effects of Recent Changes in Prescription Drug Promotion
ReportThe rapid increase in DTC advertising for prescription drugs has focused attention on its role in drug spending and prescribing. A new study by researchers at Harvard University and the Massachusetts Institute of Technology looks at the effect of direct-to-consumer (DTC) advertising on spending for prescription drugs.
-
The Current State of Retiree Health Benefits: Findings from the Kaiser/Hewitt 2002 Retiree Health Survey
ReportThis report presents findings from a study of large private-sector employers conducted by researchers at Hewitt Associates and the Kaiser Family Foundation between July and September of 2002.
-
What Will Candidates Say About Medicare This Election?
PerspectiveIn this article for the American Society of Aging’s Generations Today, KFF Senior Vice President Tricia Neuman examines what President Trump and former Vice President Joe Biden are saying about key issues for Medicare beneficiaries, including drug prices and affordability, as well as what they aren’t saying about Medicare’s financing.
-
What Happens to Medicaid Drug Policy if the ACA is Overturned?
Issue BriefThe repeal of the ACA could mean loss of Medicaid coverage for up to 15 million that were enrolled in the ACA Medicaid expansion group prior to the COVID-19 pandemic; however, repeal could also mean significant changes to Medicaid prescription drug policy with implications for state and federal spending for prescription drugs for non-expansion Medicaid enrollees.
-
Health Affairs Article: Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available
Issue BriefIn an article in Health Affairs, KFF's Juliette Cubanski, Sarah True and Tricia Neuman, and several other co-authors, explore how often brand-name drugs receive favorable formulary inclusion relative to generics in the Medicare Part D program's prescription drug plans.
-
Visualizing Health Policy: US Statistics on Surprise Medical Billing
News ReleaseThis Visualizing Health Policy infographic looks at the experience of unexpected or “surprise” medical bills in the United States. Out-of-network charges typically expose individuals to higher cost-sharing when they use services, and may lead to balance billing – in which providers bill patients directly, and often unexpectedly, at a higher rate.
-
Medicare Spending at the End of Life: A Snapshot of Beneficiaries Who Died in 2014 and the Cost of Their Care
Issue BriefThis data note provides a snapshot of Medicare beneficiaries who died in 2014 and their Medicare spending at the end of life. It examines Medicare per capita spending trends over time since 2000 and in 2014, both overall and by type of service, for beneficiaries in traditional Medicare who died in a given year compared to those who survived the year.